The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 2.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 2.
Number 5: Medicines for Europe has released a new report, prepared by the Economist Intelligence Unit, that attempts to address the problem of medicines shortages in Europe.
Number 4: FDA Commissioner, Dr Scott Gottlieb, announced 2 new initiatives this week. One is aimed at increasing competition for complex generics, and the other streamlines the process for patients to receive investigational drugs for compassionate use.
Number 3: In a new report on drug spending, pharmacy benefit manager Express Scripts says that a group comprising less than 1% of US patients accounts for more than 20% of total pharmacy spending.
Number 2: Allergan is being sued by fellow Irish drug maker, Shire, over its embattled dry eye drug, Restasis.
Number 1: A newly published case report suggests that biosimilar infliximab could present a new treatment option for patients with HIV who develop mycobacterial immune reconstitution inflammatory syndrome.
Finally, last week, our newsletter asked for your input on how suffixes to biosimilars’ names should be addressed. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.